Eikon Therapeutics

Eikon Therapeutics is a biotechnology company that integrates advanced engineering with molecular and cell biology to accelerate drug discovery and development. They leverage proprietary single-molecule tracking technology to uncover biological processes in living cells with unprecedented precision, with the goal of bringing important new medicines to people suffering from grievous illness.

Funding Round: Series D

Funding Amount: $350.7M

Date: 26-Feb-2025

Investors: Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., UC Investments (Office of the Chief Investment Officer of the Regents of the University of California)

Markets: Biotech

HQ: Hayward, California, United States

Founded: 2019

Website: http://www.eikontx.com

LinkedIn: https://www.linkedin.com/company/eikon-therapeutics-inc/

Twitter: https://twitter.com/eikontx

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/eikon-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/432611-20